February 2013, Volume 63, Issue 2

Student's Corner

Evaluation of iron serum level in Alzheimer disease

Mohamad Goldust  ( Medical Student, Student Research Committee, Tabriz University of Medical Sciences, Tabriz, Iran. )
Aliakbar Taheraghdam  ( Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran. )
Mahnaz Talebi  ( Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran. )
Mehdi Farhoudi  ( Department of Neurology, Tabriz University of Medical Sciences, Tabriz, Iran. )
Jafar Majidi  ( Department of Immunology, Tabriz University of Medical Sciences, Tabriz, Iran. )

Madam, Alzheimer disease is the most common and important degenerative disease of brain.1,2 Several theories have been raised for Alzheimer disease including genetic deficiencies, slowly-progressive viral diseases, neutrophilic factors deficiencies, amyloid, free radicals, mitochondrial deficiencies and glutamate poisoning.3,4 One important phenomenon in these diseases is changes observed in copper and iron homeostasis.5,6 Since iron serum level has been less considered in Alzheimer patients, this study aimed at evaluating the iron serum level in Alzheimer disease. In a one year case-control study, a group of patients with definite diagnosis of Alzheimer disease were evaluated by Global Deterioration Scale (GDS) for their disease severity, the serum ferritin level also has been measured by atomic absorption method in each individuals. We also measured the serum ferritin level in a group of controls. The serum ferritin level was compared between the case and the control groups, and also its relation with disease severity was assessed. Fifty patients with the mean age of 71.34±6.69 and 50 healthy persons, with the mean age of 68.96±6.39 were studied. The serum ferritin level was 0.41±0.16 ppm and 0.46±0.20 ppm, respectively (P=0.229). There was no significant correlation between the serum ferritin level and the severity of Alzheimer disease (r=0.186, P =0.195). Mean iron serum level was 0.41±0.16 in Alzheimer patients and 0.46±0.20 in healthy subjects. There is not statistically significant difference between Alzheimer patients and healthy persons considering serum iron level. Mean serum iron level in patients suffering from grade 2 Alzheimers is meaningfully less than others.

References

1. Bonda DJ, Lee HG, Blair JA, Zhu X, Perry G, Smith MA. Role of metal dyshomeostasis in Alzheimer\\\'s disease. Metallomics 2011; 3: 267-70.
2. Railey AM, Groeber CM, Flinn JM. The effect of metals on spatial memory in a transgenic mouse model of Alzheimer\\\'s disease. J Alzheimers Dis 2011; 24: 375-81.
3. Frykman S, Teranishi Y, Hur JY, Sandebring A, Yamamoto NG, Ancarcrona M, et al. Identification of two novel synaptic gamma-secretase associated proteins that affect amyloid beta-peptide levels without altering Notch processing. Neurochem Int 2012; 61: 108-18.
4. Castellani RJ, Moreira PI, Perry G, Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. Biofactors 2012; 38: 133-8.
5. Squitti R. Metals in Alzheimer\\\'s disease: a systemic perspective. Front Biosci 2012; 17: 451-72.
6. Chen WT, Liao YH, Yu HM, Cheng IH, Chen YR. Distinct effects of Zn2+, Cu2+, Fe3+, and Al3+ on amyloid-beta stability, oligomerization, and aggregation: amyloid-beta destabilization promotes annular protofibril formation. J Biol Chem 2011; 286: 9646-56.

Journal of the Pakistan Medical Association has agreed to receive and publish manuscripts in accordance with the principles of the following committees: